Interpreting Anti-IL5 Trial Data: Implications for Asthma, EoE and HES Pathophysiology
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, Coronada
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Steven J. Ackerman , PhD
Sameer K. Mathur , MD PhD FAAAAI
Learning Objectives:
  1. Discuss the different types of anti-IL-5 therapy in use in clinical trials
  2. Review the outcomes of anti-IL-5 therapy for asthma, eosinophilic esophagitis and hypereosinophilic syndrome
  • AAAAI Session 2015.pdf (225.7 kB)
  • See more of: Seminar